We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
I Agree
Email registered. Please sign in.×
Enter your contact to build trust with supplier(s)×
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email :PharmaSources@imsinoexpo.com
Whatsapp :+86-13621645194
Tianjin Minxiang Biomedical INC. was founded in 2005. which has more than 400 employees. With a registered capital of USD 16.44million dollars , we was officially listed in 2015 (stock code: 834738). Minxiang Pharmaceutical Co.,Ltd.,a subsidiary of Tianjin Minxiang Biomedical INC. boast a large-scle amantadine hydrochloride production base in the word,equipped with the leading giobal production line of adamantane series Products. I t is the leading enterprise among the domestic industries of adamantane series,special Pharmaceutical intermediates and raw matrerials,especially in the field of and hypoglycemic drugs .With production,standard and sound quality sustem,together with the long-term operating mechanism of ISO9001,ISO14001,ISO45001 and GMP,the company follow the parameter release quality control sustemwhich is higher than the GMP requirements,so as to ensure the quality of the product effectively. In accordanc with the business philosophy of "aim at innovation and estaablish a faith in quality",following the core values of customer first and keep promise,MinxiangPharmaceutical Company provides customers with high quality products and first-class service,sincerely hoping to coperate with friends from all sectors to achieve win-win coperation,innovation and common denelopment.